Have a personal or library account? Click to login
Olanzapine - Focus on the Cardiometabolic Side Effects Cover

Olanzapine - Focus on the Cardiometabolic Side Effects

EABR. Experimental and Applied Biomedical Research
Volume 22 (2021): Issue 2 (June 2021)
By: Miroslav Mitrovic,  Tamara Nikolic,  Marko Turnic and  Dusan Djuric  
Open Access
|Aug 2021

Authors

Miroslav Mitrovic

Pharmanova doo Beograd, Serbia

Tamara Nikolic

University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia

Marko Turnic

Serbia

Dusan Djuric

duca1duca@gmail.com

University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia
DOI: https://doi.org/10.1515/sjecr-2017-0054 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Journal RSS Feed
Language: English
Page range: 167 - 174
Submitted on: Aug 29, 2017
Accepted on: Sep 4, 2017
Published on: Aug 5, 2021
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
olanzapine,
weight gain,
dyslipidemia,
cardiovascular disease
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2021 Miroslav Mitrovic, Tamara Nikolic, Marko Turnic, Dusan Djuric, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 22 (2021): Issue 2 (June 2021)Next article